Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

Leukemia. 2012 Jan;26(1):172-7. doi: 10.1038/leu.2011.187. Epub 2011 Aug 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Dasatinib
  • Drug Resistance, Neoplasm
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*

Substances

  • 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Dasatinib